Active, not recruitingPhase 1NCT03962465

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Virginia
Principal Investigator
Michael Douvas, MD
University of Virginia
Intervention
Inotuzumab ozogamicin(drug)
Enrollment
36 target
Eligibility
16-60 years · All sexes
Timeline
2022 – 2026

Study locations (4)

Collaborators

Pfizer · Vanderbilt University · University of Wisconsin, Madison · Virginia Commonwealth University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03962465 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials